Apnimed doses first patient in phase 2 trial of AD109 in obstructive sleep apnea

This article was originally published here

If successful, this pharmacologic approach could substantially change the treatment paradigm for OSA patients. “There is a clear unmet need for an approach that addresses the underlying cause

The post Apnimed doses first patient in phase 2 trial of AD109 in obstructive sleep apnea appeared first on Pharmaceutical Business review.